Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND HF LOOP)

December 22, 2025 updated by: Aaron Henry, Government of Jersey

Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND-HF LOOP)

The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure.

The main questions it aims to answer are:

  1. Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care?
  2. Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease?

This is a cluster randomised controlled trial, which means that whole GP practices, rather than individual patients, are randomly assigned to one of two approaches:

  1. NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test
  2. Usual care, in which patients continue to be managed as they normally would without proactive screening

Participants will:

Be identified from GP records if they are prescribed loop diuretics and have no prior diagnosis of heart failure

In screening practices, be invited to attend for a free finger-prick NT-proBNP blood test and brief questionnaire

Be referred to the heart failure team and invited for an echocardiogram (a heart ultrasound scan) and further assessment if their NT-proBNP level is higher than 125 pg/mL

Researchers will compare outcomes between screening and usual-care practices after 12 months, focusing on new diagnoses of heart failure. They will also look at other important cardiovascular findings, such as new arrhythmias, valve disease, and heart failure hospitalisation rates.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Jersey
      • Saint Helier, Jersey
        • Jersey General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Receiving a loop diuretic (furosemide, bumetanide or torsemide)
  • No coded diagnosis of heart failure in GP records
  • Never had a natriuretic peptide test
  • Willing to have a blood test for NT-proBNP

Exclusion Criteria:

  • Clinical Frailty Score 7 or above on Rockwood frailty scale
  • Prior diagnosis of heart failure
  • Prior natriuretic peptide testing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention - NTproBNP Screening
Half of the island's GP surgeries will be randomly allocated to the intervention arm, whereby patients receiving a loop diuretic but without a diagnosis of heart failure or natriuretic peptide testing will be invited for a point of care NT-proBNP test.
Diagnostic test: NT-proBNP screening
Patients in the intervention arm will be invited for a free point of care NT-proBNP blood test
No Intervention: Control - Usual care
Half of the island's GP surgeries will be randomly allocated to the control arm, whereby patients will continue with usual clinical care and won't be approached by the study team.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
New Heart Failure diagnosis at 12 months
Time Frame: 12 months from practice enrollment
12 months from practice enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All cause mortality
Time Frame: 12 months
12 months
New clinically relevant cardiovascular disease
Time Frame: 12 months
This will include moderate valvular disease and arrhythmia (eg, AF).
12 months
Heart Failure Hospitalisations
Time Frame: 12 months
12 months

Other Outcome Measures

Outcome Measure
Time Frame
Number of patients with heart failure but not coded in primary care record
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Government of Jersey

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2025

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

December 22, 2025

First Submitted That Met QC Criteria

December 22, 2025

First Posted (Actual)

January 6, 2026

Study Record Updates

Last Update Posted (Actual)

January 6, 2026

Last Update Submitted That Met QC Criteria

December 22, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025HCJREC03

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe